Royalty Pharma RPRX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | —— | $18.82M-51.9% | $39.14M+13.8% | ||
| $2.49B-10.1% | $2.77B-7.3% | $2.99B+39.4% | $2.14B+6.3% | ||
| $21.23M+7.3% | $19.79M+1,274% | $1.44M-99.7% | $542.04M+767% | ||
| $1.7B-32.2% | $2.51B+18.4% | $2.12B+21.5% | $1.74B-20.5% | ||
| -$1.61B+39.7% | -$2.68B-29.2% | -$2.07B— | —— | ||
| $1.23B+434% | $229.65M— | —— | —— | ||
| $167.48M+33.8% | $125.16M+4.7% | $119.53M-17.1% | $144.12M— | ||
| -$1.79M— | —— | —— | $0— | ||
| —— | —— | -$2.15B-127% | -$944.86M— | ||
| -$310.33M— | —— | -$1.23B-827% | $169.7M— | ||
| $276.29M+73.1% | $159.57M-5.7% | $169.17M-0.6% | $170.14M+30.4% | ||
| —— | —— | $18.82M-51.9% | $39.14M+13.8% | ||
| —— | —— | $52M— | —— | ||
| $10.94M— | —— | $0— | —— | ||
| $288.14M+22.0% | $236.23M-2.8% | $243.01M+9.0% | $222.97M+20.8% | ||
| $114.02M+4.8% | $108.85M-31.5% | $158.84M+127% | $69.89M+58.4% | ||
| $3.35B+12.4% | $2.98B-6.8% | $3.2B+27.7% | $2.51B+8.3% | ||
| $720K-95.1% | $14.65M+1,025% | $1.3M-98.2% | $72.94M-51.7% | ||
| $271.31M+262% | $75M— | —— | $0-100% | ||
| —— | $62.5M— | $0-100% | $87.79M-35.0% | ||
| $34.72M-64.8% | $98.58M— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| $21.23M+7.3% | $19.79M+1,274% | $1.44M-99.7% | $542.04M+767% | ||
| $0— | $0-100% | $4.97M— | $0— | ||
| $378.25M+0.5% | $376.47M+5.1% | $358.33M+7.5% | $333.32M+16.9% | ||
| $167.48M+33.8% | $125.16M+4.7% | $119.53M-17.1% | $144.12M— | ||
| $354.9M-2.0% | $362.28M— | —— | —— | ||
| $5.7M+30.7% | $4.36M-37.1% | $6.93M+13.0% | $6.13M-83.4% | ||
| —— | $747K+37.6% | $543K-48.7% | $1.06M-85.6% | ||
| -$1.79M— | —— | —— | $0— | ||
| $34.31M-26.2% | $46.48M-35.1% | $71.6M+187% | $24.98M+697% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
